[Schizophrenic deficit syndrome and neurologic tolerance].
Risk factors promoting the occurrence of neuroleptic-related tardive dyskinesia remain poorly understood. It has been hypothesized that type II schizophrenia, based on Crow's classification, would be more liable to this complication due to cerebral structural abnormalities involved in the pathogenesis of schizophrenia characterized by deficitary symptoms. Association between tardive dyskinesia and cognitive deficit is currently the most firmly established. Data in the literature concerning the association between tardive dyskinesia and the other features of type II schizophrenia are more contradictory.
Verdoux
H
H
IPSO, Centre Carreire, Université de Bordeaux II, Service Universitaire de Psychiatrie.
Bourgeois
M
M
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003863:Depression / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis* / Q000523:psychology; D006801:Humans; D011569:Psychiatric Status Rating Scales; D012307:Risk Factors; D012559:Schizophrenia / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents
Déficit et tolérance neurologique.